- cafead   Aug 25, 2020 at 10:23: PM
via Sarepta Therapeutics (SRPT) announced Tuesday that the Food and Drug Administration agreed to an accelerated approval process for its treatment for certain patients with Duchenne muscular dystrophy. The news boosted SRPT stock.
article source
article source